The estimated Net Worth of Jacob Vincent Micallef is at least $337 mil dollars as of 29 August 2023. Jacob Micallef owns over 20,000 units of VolitionRX Ltd stock worth over $38,445 and over the last 9 years he sold VNRX stock worth over $0. In addition, he makes $298,832 as Chief Scientific Officer at VolitionRX Ltd.
Sign up
Jacob Micallef VNRX stock SEC Form 4 insiders trading
Jacob has made over 9 trades of the VolitionRX Ltd stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of VNRX stock worth $25,000 on 29 August 2023.
The largest trade he's ever made was exercising 130,000 units of VolitionRX Ltd stock on 10 August 2020 worth over $357,500. On average, Jacob trades about 9,287 units every 78 days since 2015. As of 29 August 2023 he still owns at least 55,000 units of VolitionRX Ltd stock.
You can see the complete history of Jacob Micallef stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jacob Micallef biography
Dr. Jacob Micallef serves as the Chief Scientific Officer of the Company. Dr. Micallef also served as a Director of Belgian Volition between August 10, 2011 and March 31, 2016. Prior to the Share Exchange Agreement, he served as Chief Scientific Officer of Belgian Volition from October 11, 2010 to December 31, 2014, but was not otherwise involved with Singapore Volition. Dr. Micallef joined Cronos Therapeutics Limited, or Cronos, in 2004 and, in 2006, Cronos was listed in the U.K. on the AIM, becoming Valirx plc, or Valirx. Dr. Micallef continued to work as Technical Officer for Valirx, where he in-licensed the NucleosomicsTM technology and co-founded ValiBio SA, which is now Belgian Volition. From 2004 to 2007, he taught “science and enterprise” to science research workers from four universities at CASS Business School before joining Cronos. In 2001, Dr. Micallef co-founded Gene Expression Technologies, after getting his MBA in 1999, where he successfully led the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer AG. Over a 15-year period, starting in 1985, Dr. Micallef worked for the World Health Organization, or WHO. While working for WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990, he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture (previously outsourced to Abbott Diagnostics Inc.) and world-wide distribution of these products for WHO. Also in 1990, he started a “not-for-profit” WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide. Dr. Micallef has over 20 years of experience in research and development and in the management of early stage biotechnical companies, including the manufacture of biotechnology products and
What is the salary of Jacob Micallef?
As the Chief Scientific Officer of VolitionRX Ltd, the total compensation of Jacob Micallef at VolitionRX Ltd is $298,832. There are 5 executives at VolitionRX Ltd getting paid more, with Cameron Reynolds having the highest compensation of $517,691.
How old is Jacob Micallef?
Jacob Micallef is 63, he's been the Chief Scientific Officer of VolitionRX Ltd since 2015. There are 6 older and 14 younger executives at VolitionRX Ltd. The oldest executive at VolitionRX Ltd is Dr. Martin Charles Faulkes Ph.D., 77, who is the Exec. Chairman.
What's Jacob Micallef's mailing address?
Jacob's mailing address filed with the SEC is 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, NV, 89014.
Insiders trading at VolitionRX Ltd
Over the last 12 years, insiders at VolitionRX Ltd have traded over $775,239 worth of VolitionRX Ltd stock and bought 1,908,474 units worth $44,487,770,972 . The most active insiders traders include Guy Archibald Innes, Cameron John Reynolds, eMartin Charles Faulkes. On average, VolitionRX Ltd executives and independent directors trade stock every 43 days with the average trade being worth of $27,899. The most recent stock trade was executed by Guy Archibald Innes on 20 August 2024, trading 150,000 units of VNRX stock currently worth $100,500.
What does VolitionRX Ltd do?
volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.
What does VolitionRX Ltd's logo look like?
Complete history of Jacob Micallef stock trades at VolitionRX Ltd
VolitionRX Ltd executives and stock owners
VolitionRX Ltd executives and other stock owners filed with the SEC include:
-
Cameron Reynolds,
President, Chief Executive Officer, Director -
Cameron Reynolds MBA,
Founder, Group CEO, Pres & Director -
Jason Terrell,
Chief Medical Officer and Head of US Operations -
Dr. Jason Bradley Terrell,
Chief Medical Officer & Head of U.S. Operations -
David Vanston,
Chief Financial Officer, Treasurer -
Jacob Micallef,
Chief Scientific Officer -
Martin Faulkes,
Executive Chairman of the Board -
Rodney Rootsaert,
Corporate Secretary -
Dr. Martin Charles Faulkes Ph.D.,
Exec. Chairman -
Dr. Jacob Vincent Micallef,
Chief Scientific Officer -
Dr. Salvatore Thomas Butera,
Chief Exec. Officer of Volition Veterinary Diagnostics Devel. LLC -
Scott Powell,
IR Contact Officer -
Guy Innes,
Independent Director -
Edward Futcher,
Independent Director -
Alan Colman,
Independent Director -
Phillip Barnes,
Independent Director -
Gaetan Michel,
Chief Executive Officer of Belgian Volition -
Jasmine Kway,
Chief Executive Officer of Singapore Volition -
Nick Plummer,
Group Gen. Counsel -
Scott Powell Ph.D.,
Exec. VP of Investor Relations & CFO of Volition America Inc -
Dr. Mark Eccleston M.B.A., Ph.D.,
Chief Technology Officer -
Dr. Gaetan Michel Ph.D.,
Chief Operating Officer -
Terig Hughes,
Group CFO & Treasurer -
Corp Ltd Cotterford Co Ltd ...,
-
Richard Brudnick,
-
Habib Skaff,
Director -
David Matthew Kratochvil,
Chief Financial Officer -
Rodney Gerard Concord Inter...,
Secretary -
Nicholas Plummer,
GC - Volition Diagnostics -
Ann Louise Batchelor,
Group Chief Marketing Officer -
Kim Nguyen,
-
Terig Hughes,
Chief Financial Officer -
Mickie Henshall,
-
Gael Forterre,
Chief Commercial Officer -
Corp Ltd Hever Investments ...,
-
Salvatore Thomas Butera,
CEO - Volition Veterinary